Gyan Research weekly newsletter on #healthcare sector

1. Policy News
 Transfer of blood from one bank to another approved
The union health ministry has approved the transfer of blood from one bank to another. It has prescribed
detailed guidelines for efficient and proper transportation of blood that will make blood accessible in
places of scarcity, thereby saving lives. It has also fixed a "non-cash" exchange value of INR 1,600 per litre
for extra plasma, which is available in some Indian blood banks. The move will enhance access to
essential life-saving medicines, derived from plasma, and reduce India’s import of these products. Earlier,
surplus plasma was traded without any regulation. These steps were taken as per the recommendation of
the National Blood Transfusion Council.
Industry News
 Two-year homoeopathy pharmacy diploma course introduced
The Board of Homoeopathic System of Medicine under the Delhi government will launch a two-year
homoeopathy pharmacy diploma course, which will provide both theoretical and practical training. This
course will enable aspiring pharmacists in this field to operate their own dispensaries as well as secure
job opportunities in state government hospitals, homoeopathic medical colleges, private homoeopathic
clinics and state government dispensaries, among others. The eligibility criterion for the homoeopathy
compounder’s course is a pass certificate in intermediate with science stream.
 Clinical testing of ayurvedic, homeopathy medicines commences
The central government has started clinical testing of various homoeopathy and ayurvedic medicines on
patients suffering from different tropical diseases and some virus-borne diseases. These trials are being
conducted both in government and in private hospitals, where patients are kept under observation.
Based on the observations, the trial is taken to the next level. So far, around 500 patients have enrolled in
different hospitals in Delhi and NCR. The Central Council for Research in Ayurvedic Sciences is
coordinating and monitoring the progress of these studies and compiling them to create scientific
evidence documents that support the efficacy of traditional medicines. This initiative is an attempt to
develop traditional Indian medicines.
 Aurobindo Pharma to launch Tramadol in the US
Aurobindo Pharma will launch Tramadol Hydrochloride extended-release tablets in the US market in
January 2016. The company has received the final Abbreviated New Drug Application (ANDA) approval
from the US Food and Drug Administration (USFDA) to manufacture and market the medicine. These
drugs are used for treating moderate to severe pain in adults requiring continuous treatment for an
extensive period of time. The drug has a projected market size of USD 56 million for 12 months ending
August 2015. Aurobindo has a total of 217 ANDA approvals from USFDA.
© Gyan Research and Analytics Pvt. Ltd., 2015 1
Healthcare News
October 17, 2015 – October 23, 2015

2. © Gyan Research and Analytics Pvt. Ltd., 2015 2
 Multi-specialty hospital OPD inaugurated in Delhi
The out-patient department (OPD) of an under-construction multi-specialty eight storeyd hospital in
Kalakaji area in South Delhi has been thrown open for treatment. The move came in an effort to combat
the outbreak of dengue and swine-flu in Delhi. The construction cost of the hospital is estimated at over
INR 52 crore and it is spread over 8,540 square meters. A 100-bedded facility, the hospital will provide
effective, affordable, quality and secondary as well as tertiary healthcare facilities on completion.
Investment News
 Recipharm buys majority stake in Nitin Lifesciences
Swedish drug manufacturing firm, Recipharm, has purchased 74 equity stake in Nitin Lifesciences - a
domestic sterile injectable manufacturing firm - for INR 671 crore. This move will help Recipharm to
expand its operations in emerging markets. The drug manufacturing company expects to complete the
deal after getting regulatory approval from the Foreign Investment Promotion Board. Currently, Nitin
Lifesciences focuses on the Indian market and supplies to drug makers from its three manufacturing sites.
This agreement will reinforce India's long-term attractiveness as a sterile injectable market. Ernst &
Young India was the advisor to Nitin Lifescience, while Veritas Global advised Recipharm.
 AHLL to raise INR 500 crore
Apollo Health and Lifestyle Limited (AHLL) will be diluting nearly 20 percent of its stake to raise INR 500
crore by the end of 2015. The company is in advanced talks with global private equity funds. With the
funds, Apollo Hospitals Group's subsidiary plans to expand its network and enter new markets. It is
particularly looking to grow its primary care offerings and specialty formats. AHLL has over 150 centres
across the country and in the Middle East.
Healthcare News
October 17, 2015 – October 23, 2015
Weekly Snapshot
Top Three Pharmaceutical Company as on September 2015
Companies Market Growth (in percent)
Zydus 12.60
Lupin 12.40
Sun Pharma 11.80
Source: AIOCD PharmaSoftechAWACS

3. © Gyan Research and Analytics Pvt. Ltd., 2015 3
Market Entry
Strategies
Market/
Marketing
Research
Pre-Feasibility,
Feasibility & TEV
Studies
Equity
Research
& Valuation
Economic
Intelligence
Our Business Practices
Business
Research
Central Delivery
Centre
BD-9, Sector-1,
Salt Lake City
Kolkata - 700 064,
India
Phone: +91-33-
40060084
Corporate Office
LG 37-38, Ansal
Fortune Arcade,
Sector - 18,
Noida - 201 301
Delhi NCR, India
Phone: +91-120-
2511945
E-mail: reports@gyananalytics.com
Website: www.gyananalytics.com
Branch Office -
Mumbai
Branch Office
- Bangalore
Branch Office
- Hyderabad
Healthcare News, October 17, 2015 – October 23, 2015